Back to top

Arena Pharmaceuticals, Inc. Enters Oversold Territory
October 18, 2013

Read MoreHide Full Article

Arena Pharmaceuticals, Inc.’s (ARNA - Free Report) share price has entered into oversold territory with an RSI value of 28.73. The Zacks Consensus Estimate on Arena Pharmaceuticals, Inc.’s earnings for the full year period has loss by 0.01 cents over the past two months to $-0.14 per share. Currently, Arena Pharmaceuticals, Inc. is a Zacks #2 Rank (“Buy”), suggesting that now might be a good time to get in on (ARNA - Free Report) after its recent drop.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Arena Pharmaceuticals, Inc. (ARNA) - free report >>

More from Zacks Tale of the Tape

You May Like